​Pharmacology - Quinupristin + Dalfopristin

​Pharmacology - Quinupristin + Dalfopristin
Quinupristin and Dalfopristin work together to prevent bacteria from making proteins by preventing the conversion of messenger RNA into proteins.

Action Process 
Dalfopristin prevents aa-tRNA from attaching to the ribosome and preventing peptide bond synthesis; quinupristin causes peptidyl-tRNA to dissociate. Half life is one to three hours; administered intravenously; processed by the liver. The action of ciclosporin, midazolam, nifedipine, and antidysrhythmics (lidocaine, disopyramide) is enhanced because it inhibits metabolism.
Practical Applications in Healthcare
The most severe Gram-positive infections that do not respond to other antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA), skin and soft tissue infections, pneumonia contracted in a hospital setting, and vancomycin-resistant Enterococcus faecium.

Potential Side Effects 
gastrointestinal side effects, headache, muscular and joint discomfort, rash, pruritis, reactions at the injection site, low white blood cell count, anemia.